Table 1.
Clinical characteristics of patients with polymyositis or dermatomyositis and control persons
| All patients (N = 90) | Controls (N = 48) | p value | |
|---|---|---|---|
| Age (years) | 60.3 ± 1.3 | 59.9 ± 1.2 | 0.82 |
| Body weight (kg) | 78.7 ± 1.9 | 74.7 ± 1.8 | 0.13 |
| Height (m) | 1.70 ± 0.01 | 1.69 ± 0.01 | 0.87 |
| Body mass index | 27.3 ± 0.6 | 25.9 ± 0.4 | 0.06 |
| Female, N (%) | 57 (63) | 32 (67) | 0.71 |
| PM/DM, N (%) | 60 (67)/30 (33) | ||
| MMT8, 0–80 | 72.5 ± 0.8 | ||
| HAQ, 0–3 | 0.68 ± 0.08 | ||
| MD global activity, VAS 0–10 cm | 2.64 ± 0.25 | ||
| PA global activity, VAS 0–10 cm | 4.92 ± 0.31 | ||
| CK relative valuea | 2.99 ± 0.75 |
MMT8: each of eight muscle groups scored 0–10; lower scores indicate reduced strength. HAQ, MD and PA global activity: higher scores indicate more severe disease activity
PM polymyositis, DM dermatomyositis, MMT8 manual muscle test including eight muscle groups, HAQ Health Assessment Questionnaire, MD physician, VAS visual analogue scale, PA patient
aThe value of creatine kinase divided by the local upper reference value